Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

The role of Herceptin in early breast cancer.

Subramanian A, Mokbel K.

Int Semin Surg Oncol. 2008 Apr 28;5:9. doi: 10.1186/1477-7800-5-9.

2.

From HER2 to herceptin.

Mokbel K, Hassanally D.

Curr Med Res Opin. 2001;17(1):51-9. Review.

PMID:
11464447
3.
4.

Maximizing the response to Herceptin therapy through optimal use and patient selection.

Leyland-Jones B.

Anticancer Drugs. 2001 Dec;12 Suppl 4:S11-7. Review.

PMID:
11989522
5.

Herceptin: the future in adjuvant breast cancer therapy.

Piccart-Gebhart MJ.

Anticancer Drugs. 2001 Dec;12 Suppl 4:S27-33. Review.

PMID:
11989524
6.

HER2-directed therapy for metastatic breast cancer.

Jelovac D, Emens LA.

Oncology (Williston Park). 2013 Mar;27(3):166-75. Review.

PMID:
23687784
7.

Her2-positive breast cancer: herceptin and beyond.

Dean-Colomb W, Esteva FJ.

Eur J Cancer. 2008 Dec;44(18):2806-12. doi: 10.1016/j.ejca.2008.09.013. Epub 2008 Nov 18. Review.

PMID:
19022660
8.

Anti-HER2 treatment and breast cancer: state of the art, recent patents, and new strategies.

Daniele L, Sapino A.

Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):9-18. Review.

PMID:
19149684
9.

[Herceptin-based therapy for breast cancer].

Tokuda Y, Saito Y, Suzuki Y.

Nihon Rinsho. 2006 Mar;64(3):540-5. Review. Japanese.

PMID:
16529047
10.

Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.

Chung A, Cui X, Audeh W, Giuliano A.

Clin Breast Cancer. 2013 Aug;13(4):223-32. doi: 10.1016/j.clbc.2013.04.001. Review.

12.

[Genetic testing for effective Herceptin therapy].

Watanabe T, Katsumata N, Ando M, Mukai H, Shimizu C, Kitagawa R, Saijo NG.

Nihon Rinsho. 2002 Mar;60(3):603-11. Review. Japanese.

PMID:
11904980
13.
14.

[Breast cancer and herceptin].

Cornez N, Piccart MJ.

Bull Cancer. 2000 Nov;87(11):847-58. Review. French.

15.

Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.

Esteva FJ, Pusztai L.

Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):5-16. Review.

PMID:
19364051
16.

Targeted therapies in breast cancer: established drugs and recent developments.

Fischgräbe J, Wülfing P.

Curr Clin Pharmacol. 2008 May;3(2):85-98. Review.

PMID:
18690883
17.

Prognostic and predictive value of HER2/neu oncogene in breast cancer.

Masood S, Bui MM.

Microsc Res Tech. 2002 Oct 15;59(2):102-8. Review.

PMID:
12373720
18.

Trials of new combinations of Herceptin in metastatic breast cancer.

Thomssen C.

Anticancer Drugs. 2001 Dec;12 Suppl 4:S19-25. Review.

PMID:
11989523

Supplemental Content

Support Center